All Hypercholesterolaemia articles
-
Medicines appraisal cardsNICE Technology Appraisal 694: Bempedoic acid▼ with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
The production of this Guidelines card has been commissioned and funded by Daiichi Sankyo UK.
View Bempedoic acid (Nilemdo®▼) & Bempedoic acid and ezetimibe (Nustendi®▼) prescribing and adverse event reporting information
BEM/21/0374 May 2021 -
Implementing guidelines
Familial hypercholesterolaemia: case finding, assessment, and management
Sadaf Qureshi and Dr Nadeem Qureshi review updated NICE guidance on familial hypercholesterolaemia and discuss the importance of proactive identification of this patient group in primary care
-
News
Updated guidance on familial hypercholesterolaemia published by NICE
NICE has published an update to NICE Clinical Guideline 71 on Familial hypercholesterolaemia: identification and management.
-
Hot topic
Common genetic conditions: a guide for GPs—part 1
Drs Rosalyn Jewell, Schaida Schirwani, and Jude Hayward look at the role of GPs in identifying and managing FH, ADPKD, Down syndrome, and AAT deficiency
-
Implementing guidelines
Greater progress is needed in case identification of FH
Dr David Milne discusses how implementation of the NICE guideline on familial hypercholesterolaemia requires significant improvements in access to local services
-
Implementing guidelines
The Simon Broome criteria should be used to detect FH
Drs Kathy Greenough and Kate Cushing outline the NHS North of Tyne approach to implementing the NICE guideline on familial hypercholesterolaemia
-
Implementing guidelines
NICE guideline aims to improve diagnosis and management of FH
Dr Mary Seed explains how familial hypercholesterolaemia is an under-recognised condition that can be managed effectively with pharmacotherapy and lifestyle modification
-
Personal view
SEAS trial and cancer risk: should prescribing change?
At present, there is a lack of credible evidence linking the use of ezetimibe plus statin therapy to cancer incidence, says Dr Alan Begg
-
Personal view
Lipid lowering: clinical outcome evidence should be followed
Dr Alan Begg discusses the latest results from the ENHANCE trial and their implications for the use of ezetimibe
-
Personal view
Lowering cholesterol levels reduces CVD mortality
Dr Alan Begg discusses how the NICE technology appraisal on ezetimibe will make it easier for GPs to reach QOF cholesterol targets
